Natixis Acquires 62,511 Shares of Teleflex Incorporated (NYSE:TFX)

Natixis increased its holdings in Teleflex Incorporated (NYSE:TFX - Free Report) by 1,990.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 65,651 shares of the medical technology company's stock after purchasing an additional 62,511 shares during the quarter. Natixis owned 0.14% of Teleflex worth $11,685,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in TFX. CANADA LIFE ASSURANCE Co increased its position in shares of Teleflex by 0.4% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 20,320 shares of the medical technology company's stock worth $3,614,000 after acquiring an additional 74 shares in the last quarter. Hengehold Capital Management LLC boosted its stake in Teleflex by 7.3% in the 4th quarter. Hengehold Capital Management LLC now owns 1,289 shares of the medical technology company's stock worth $229,000 after purchasing an additional 88 shares during the period. Exchange Traded Concepts LLC increased its holdings in Teleflex by 38.2% during the 4th quarter. Exchange Traded Concepts LLC now owns 340 shares of the medical technology company's stock worth $61,000 after purchasing an additional 94 shares in the last quarter. Isthmus Partners LLC raised its stake in shares of Teleflex by 7.3% in the 4th quarter. Isthmus Partners LLC now owns 1,535 shares of the medical technology company's stock valued at $273,000 after purchasing an additional 105 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Teleflex by 2.4% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 4,991 shares of the medical technology company's stock valued at $888,000 after purchasing an additional 118 shares in the last quarter. 95.62% of the stock is owned by institutional investors.

Teleflex Stock Performance

Shares of NYSE TFX traded up $1.66 during mid-day trading on Wednesday, reaching $133.10. 688,336 shares of the company's stock were exchanged, compared to its average volume of 627,438. The firm has a market capitalization of $6.17 billion, a price-to-earnings ratio of 26.46, a price-to-earnings-growth ratio of 1.73 and a beta of 1.19. Teleflex Incorporated has a 52 week low of $124.66 and a 52 week high of $249.91. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. The firm has a 50-day moving average price of $142.18 and a two-hundred day moving average price of $175.99.

Teleflex (NYSE:TFX - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical technology company reported $3.89 earnings per share for the quarter, topping analysts' consensus estimates of $3.86 by $0.03. The business had revenue of $795.40 million for the quarter, compared to analyst estimates of $813.24 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. Analysts predict that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, March 17th. Investors of record on Friday, March 7th were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, March 7th. This represents a $1.36 dividend on an annualized basis and a yield of 1.02%. Teleflex's dividend payout ratio is currently 95.77%.

Analyst Ratings Changes

A number of brokerages have recently commented on TFX. Mizuho set a $155.00 price objective on shares of Teleflex in a research report on Wednesday, April 16th. StockNews.com lowered shares of Teleflex from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. Piper Sandler reissued a "neutral" rating and issued a $140.00 price objective (down previously from $255.00) on shares of Teleflex in a research note on Friday, February 28th. Bank of America downgraded shares of Teleflex from a "neutral" rating to an "underperform" rating and dropped their price target for the company from $235.00 to $140.00 in a research note on Tuesday, March 4th. Finally, Citizens Jmp lowered Teleflex from an "outperform" rating to a "market perform" rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Teleflex currently has a consensus rating of "Hold" and a consensus target price of $169.63.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.